PRR23A: A Potential Drug Target and Biomarker (G729627)

Target Name: PRR23A

NCBI ID: G729627

PRR23A

PRR23A: A Potential Drug Target and Biomarker

PRR23A, short for protein responsible for regulated recombination, is a protein that is expressed in various tissues and cells of the human body. It plays a crucial role in the regulation of gene expression and is associated with various diseases, including cancer. Recent studies have identified PRR23A as a potential drug target and biomarker, which could lead to new therapeutic approaches for various diseases.

PRR23A as a drug target

PRR23A is a key regulator of gene expression, and its dysfunction has been implicated in various diseases. The protein is involved in the regulation of DNA replication, which is critical for cell growth and division. PRR23A is known to play a role in the regulation of the DNA replication machinery, and its dysfunction has been linked to the development of cancer.

Studies have shown that PRR23A is highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, the protein has been shown to be involved in the regulation of cell cycle progression, which is a critical step in the development of cancer.

PRR23A as a biomarker

PRR23A has also been identified as a potential biomarker for various diseases, including cancer. The protein is expressed in various tissues and cells of the body, including the brain, and its levels have been shown to be elevated in individuals with certain types of cancer.

Studies have shown that PRR23A is highly expressed in breast tissue, and its levels have been linked to the development of breast cancer. Additionally, the protein has been shown to be elevated in the blood of individuals with prostate cancer. These findings suggest that PRR23A could be used as a biomarker for the early detection of cancer.

PRR23A as a therapeutic target

PRR23A's involvement in the regulation of gene expression makes it a potential therapeutic target. Studies have shown that inhibiting PRR23A function can lead to the suppression of cancer growth. For example, researchers have shown that inhibiting PRR23A can cause the growth of breast cancer cells to slow down.

Additionally, PRR23A has been shown to be involved in the regulation of cell signaling pathways, which are critical for cancer growth and development. Researchers are exploring the potential of targeting these signaling pathways to inhibit the growth of cancer cells.

PRR23A as a potential drug

PRR23A's involvement in the regulation of gene expression makes it a potential drug target. Studies have shown that inhibiting PRR23A function can lead to the suppression of cancer growth, which could make PRR23A an effective tool for the treatment of cancer.

PRR23A has been shown to be involved in the regulation of the DNA replication machinery, which is critical for cell growth and division. Researchers are exploring the potential of targeting this machinery to inhibit the growth of cancer cells.

PRR23A has also been shown to be involved in the regulation of cell signaling pathways, which are critical for cancer growth and development. Researchers are exploring the potential of targeting these signaling pathways to inhibit the growth of cancer cells.

Conclusion

PRR23A is a protein that is involved in the regulation of gene expression and has been associated with various diseases, including cancer. Its dysfunction has been linked to the development of cancer, and it has also been identified as a potential drug target and biomarker. Further research is needed to fully understand the role of PRR23A in the development and treatment of cancer.

Protein Name: Proline Rich 23A

The "PRR23A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRR23A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets